Clinical Trials › NCT03523858
Active, Not RecruitingPhase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Sponsored by Hoffmann-La Roche
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 927
Target enrollment
13
U.S. states
May 2018
Start date
Nov 2026
Expected completion
Interventions / Treatments
Ocrelizumab
Conditions studied
Progressive Multiple Sclerosis (PMS)
Where this trial is running (18 sites)
California3 sites
Laguna Hills · Pasadena · San Francisco
Massachusetts2 sites
Boston · Wellesley
Ohio2 sites
Cincinnati · Cleveland
Texas2 sites
Round Rock · San Antonio
Connecticut1 site
North Haven
Florida1 site
Tampa
Illinois1 site
Chicago
Michigan1 site
Detroit
Missouri1 site
St Louis
New York1 site
Latham
Pennsylvania1 site
Philadelphia
Tennessee1 site
Cordova
Washington1 site
Seattle
Participating MS centers on MS Buddy (13)
The Elliot Lewis Center for Multiple Sclerosis Care
Wellesley, MA
Wellesley, MA
Swedish Neuroscience Institute MS Center
Seattle, WA
Seattle, WA
John L. Trotter Multiple Sclerosis Center
Saint Louis, MO
Saint Louis, MO
Lone Star Neurology of San Antonio
San Antonio, TX
San Antonio, TX
Mellen Center for MS Treatment & Research
Cleveland, OH
Cleveland, OH
USF Multiple Sclerosis Center
Tampa, FL
Tampa, FL
The Waddell Center for Multiple Sclerosis
Cincinnati, OH
Cincinnati, OH
Central Texas Neurology Consultants
Round Rock, TX
Round Rock, TX
University of Chicago MS Clinic
Chicago, IL
Chicago, IL
Neurology Clinic PC
Cordova, TN
Cordova, TN
UCSF Multiple Sclerosis Center
San Francisco, CA
San Francisco, CA
Massachusetts General Hospital MS Clinic
Boston, MA
Boston, MA
MS centers in California
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View California centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
